These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 21709197)

  • 1. Standardization of estrogen receptor measurement in breast cancer suggests false-negative results are a function of threshold intensity rather than percentage of positive cells.
    Welsh AW; Moeder CB; Kumar S; Gershkovich P; Alarid ET; Harigopal M; Haffty BG; Rimm DL
    J Clin Oncol; 2011 Aug; 29(22):2978-84. PubMed ID: 21709197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Automated measurement of estrogen receptor in breast cancer: a comparison of fluorescent and chromogenic methods of measurement.
    Zarrella ER; Coulter M; Welsh AW; Carvajal DE; Schalper KA; Harigopal M; Rimm DL; Neumeister VM
    Lab Invest; 2016 Sep; 96(9):1016-25. PubMed ID: 27348626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD68, CD163, and matrix metalloproteinase 9 (MMP-9) co-localization in breast tumor microenvironment predicts survival differently in ER-positive and -negative cancers.
    Pelekanou V; Villarroel-Espindola F; Schalper KA; Pusztai L; Rimm DL
    Breast Cancer Res; 2018 Dec; 20(1):154. PubMed ID: 30558648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Minimising immunohistochemical false negative ER classification using a complementary 23 gene expression signature of ER status.
    Li Q; Eklund AC; Juul N; Haibe-Kains B; Workman CT; Richardson AL; Szallasi Z; Swanton C
    PLoS One; 2010 Dec; 5(12):e15031. PubMed ID: 21152022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing breast biomarker status between routine immunohistochemistry and FISH studies and Oncotype DX testing, a study of 610 cases.
    Neely C; You S; Mendoza PM; Aneja R; Sahin AA; Li X
    Breast J; 2018 Nov; 24(6):889-893. PubMed ID: 30230095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative analysis of estrogen receptor expression shows SP1 antibody is more sensitive than 1D5.
    Welsh AW; Harigopal M; Wimberly H; Prasad M; Rimm DL
    Appl Immunohistochem Mol Morphol; 2013 Mar; 21(2):139-47. PubMed ID: 22820659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reliability of receptor assessment on core needle biopsy in breast cancer patients.
    Seferina SC; Nap M; van den Berkmortel F; Wals J; Voogd AC; Tjan-Heijnen VC
    Tumour Biol; 2013 Apr; 34(2):987-94. PubMed ID: 23269610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of c-erbB2, cyclin D1 and estrogen receptor and their clinical implications in the invasive ductal carcinoma of the breast.
    Lee A; Park WC; Yim HW; Lee MA; Park G; Lee KY
    Jpn J Clin Oncol; 2007 Sep; 37(9):708-14. PubMed ID: 17940078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Neoadjuvant Chemotherapy on Breast Cancer Subtype: Does Subtype Change and, if so, How? : IHC Profile and Neoadjuvant Chemotherapy.
    De La Cruz LM; Harhay MO; Zhang P; Ugras S
    Ann Surg Oncol; 2018 Nov; 25(12):3535-3540. PubMed ID: 29981025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recommendations for validating estrogen and progesterone receptor immunohistochemistry assays.
    Fitzgibbons PL; Murphy DA; Hammond ME; Allred DC; Valenstein PN
    Arch Pathol Lab Med; 2010 Jun; 134(6):930-5. PubMed ID: 20524870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estrogen receptor (ER), progesterone receptor (PR), and HER2 expression pre- and post- neoadjuvant chemotherapy in primary breast carcinoma: a single institutional experience.
    Kinsella MD; Nassar A; Siddiqui MT; Cohen C
    Int J Clin Exp Pathol; 2012; 5(6):530-6. PubMed ID: 22949935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Folate Receptor Alpha Immunohistochemistry in Cytology Specimens of Metastatic Breast Carcinoma.
    Sheikh UN; Cohen C; Siddiqui MT
    Acta Cytol; 2015; 59(4):298-304. PubMed ID: 26413911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progranulin (GP88) tumor tissue expression is associated with increased risk of recurrence in breast cancer patients diagnosed with estrogen receptor positive invasive ductal carcinoma.
    Serrero G; Hawkins DM; Yue B; Ioffe O; Bejarano P; Phillips JT; Head JF; Elliott RL; Tkaczuk KR; Godwin AK; Weaver J; Kim WE
    Breast Cancer Res; 2012 Feb; 14(1):R26. PubMed ID: 22316048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. STAT3 ser727 phosphorylation and its association with negative estrogen receptor status in breast infiltrating ductal carcinoma.
    Yeh YT; Ou-Yang F; Chen IF; Yang SF; Wang YY; Chuang HY; Su JH; Hou MF; Yuan SS
    Int J Cancer; 2006 Jun; 118(12):2943-7. PubMed ID: 16425286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Artificial Intelligence Algorithms to Assess Hormonal Status From Tissue Microarrays in Patients With Breast Cancer.
    Shamai G; Binenbaum Y; Slossberg R; Duek I; Gil Z; Kimmel R
    JAMA Netw Open; 2019 Jul; 2(7):e197700. PubMed ID: 31348505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breast cancer subtype discrimination using standardized 4-IHC and digital image analysis.
    Gándara-Cortes M; Vázquez-Boquete Á; Fernández-Rodríguez B; Viaño P; Ínsua D; Seoane-Seoane A; Gude F; Gallego R; Fraga M; Antúnez JR; Curiel T; Pérez-López E; García-Caballero T
    Virchows Arch; 2018 Feb; 472(2):195-203. PubMed ID: 28825136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunolocalization of thymidylate synthase as a favorable prognostic marker in estrogen receptor-positive breast carcinoma.
    Takagi K; Miki Y; Nakamura Y; Hirakawa H; Kakugawa Y; Amano G; Watanabe M; Ishida T; Sasano H; Suzuki T
    Histol Histopathol; 2015 Oct; 30(10):1223-32. PubMed ID: 25873048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemistry subtypes (ER/PR/HER) of breast cancer: where do we stand in the West of Saudi Arabia?
    Khabaz MN
    Asian Pac J Cancer Prev; 2014; 15(19):8395-400. PubMed ID: 25339035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significance of immunohistochemical assessment of steroid hormone receptor status for breast cancer patients.
    Kurosumi M
    Breast Cancer; 2003; 10(2):97-104. PubMed ID: 12736561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer.
    McLaughlin J; Han G; Schalper KA; Carvajal-Hausdorf D; Pelekanou V; Rehman J; Velcheti V; Herbst R; LoRusso P; Rimm DL
    JAMA Oncol; 2016 Jan; 2(1):46-54. PubMed ID: 26562159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.